Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.25 -2.63%

-$0.25 today

Market cap
$1.58B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 3.48M

Average 1.76M

VIR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Vir Biotechnology, Inc.NASDAQ: VIR

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$122.71M, compared with -$135.66M a year earlier. Trailing-twelve-month EBITDA was -$438.52M.

Context

  • EBITDA amounted to 621.5% of revenue in FY2025, down 64.3 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$163.24M (+61.7%) for the fiscal year ending Dec 2026, a step up from the +16.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$122.71M-205.5% QoQ
Last fiscal yearDec 2025
-$426.09M+16.3% YoY
LTMMar 2026
-$438.52M+24.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.5%+155.1%+145.5 pp
1 year+16.3%+61.7%+45.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(426.09M) USD
Year-over-year change
+16.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.4% is the 4th highest of 10, against a peer median of -30.1%.
  • EBITDA amounts to 669.6% of revenue for VIR, versus a peer median of 46.6%.
VIR Competitors
EBITDA for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.85M USD+305.5%—84.0%
ASMBAssembly Biosciences, Inc.LTM Mar 2026-$6.26M USD+84.1%—8.8%
NVAXNovavax, Inc.LTM Mar 2026-$42.13M USD-107.6%—7.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$46.56M USD+46.6%—67.3%
VALNValneva SELTM Mar 2026-€90.14M EUR-119.6%—57.7%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$179.89M USD-30.1%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$302.96M USD-577.6%—32.2%
VIRVir Biotechnology, Inc.LTM Mar 2026-$438.52M USD+24.4%—669.6%
BNTXBioNTech SELTM Jun 2026-€941.06M EUR-2167.6%—35.6%
MRNAModerna, Inc.LTM Sep 2026-$2.46B USD+16.4%—97.2%
Peer median (excluding VIR) —-30.1%—46.6%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.